Immune modulation by ER stress and inflammation in the tumor microenvironment

Cancer Letters

Volumn 380, Issue 1, 2016, Pages 227-236

  Rodvold, Jeffrey J ^a   Mahadevan, Navin R ^a   Zanetti, Maurizio ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell nonautonomous; Inflammation; Myeloid cells; T cells; Tumor microenvironment; Unfolded protein response

Indexed keywords

CYTOKINE; AUTACOID;

BONE MARROW CELL; CANCER CELL; CARCINOGENICITY; CELL EXPANSION; CELL FUNCTION; CELL POLARITY; CELLULAR STRESS RESPONSE; CROSS PRESENTATION; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; GENE; GRP78 GENE; GRP94 GENE; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTRINSIC ACTIVITY; IRE1 ALPHA GENE; PERK GENE; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ADAPTIVE IMMUNITY; ANIMAL; ANTIGEN PRESENTATION; ENDOPLASMIC RETICULUM; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; CYTOKINES; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MYELOID CELLS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE;

EID: 84984804842     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.009     Document Type: Review

References (179)

1. [1] Burnet, F.M., The concept of immunological surveillance. Prog. Exp. Tumor. Res 13 (1970), 1–27.
2. [2] Filaci, G., Fravega, M., Setti, M., Traverso, P., Millo, E., Fenoglio, D., et al. Frequency of telomerase-specific CD8+ T lymphocytes in cancer patients. Blood 107 (2006), 1505–1512.
3. [3] Molldrem, J.J., Lee, P.P., Wang, C., Felio, K., Kantarjian, H.M., Champlin, R.E., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med 6 (2000), 1018–1023.
4. [4] Nagorsen, D., Scheibenbogen, C., Marincola, F.M., Letsch, A., Keilholz, U., Natural T cell immunity against cancer. Clin. Cancer Res 9 (2003), 4296–4303.
5. [5] Yotnda, P., Firat, H., Garcia-Pons, F., Garcia, Z., Gourru, G., Vernant, J.P., et al. Cytotoxic T cell response against the chimeric. J. Clin. Invest, 101, 1998.
6. [6] Yotnda, P., Garcia, F., Peuchmaur, M., Grandchamp, B., Duval, M., Lemonnier, F., et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest 102 (1998), 455–462.
7. [7] Monsurro, V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M.E., Rosenberg, S.A., et al. Functional heterogeneity of vaccine-induced CD8(+) T cells. J. Immunol 168 (2002), 5933–5942.
8. [8] Monsurro, V.V., Wang, E., Yamano, Y., Migueles, S.A., Panelli, M.C., Smith, K., et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104 (2004), 1970–1978.
9. [9] Willimsky, G., Blankenstein, T., Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005), 141–146.
10. [10] Bogen, B., Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol 26 (1996), 2671–2679.
11. [11] Colella, T.A., Bullock, T.N., Russell, L.B., Mullins, D.W., Overwijk, W.W., Luckey, C.J., et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med 191 (2000), 1221–1232.
12. [12] Preynat-Seauve, O., Contassot, E., Schuler, P., Piguet, V., French, L.E., Huard, B., Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res 67 (2007), 5009–5016.
13. [13] Ochsenbein, A.F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U.S.A. 96 (1999), 2233–2238.
14. [14] Mumm, J.B., Oft, M., Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 27 (2008), 5913–5919.
15. [15] Rodriguez, P.C., Hernandez, C.P., Quiceno, D., Dubinett, S.M., Zabaleta, J., Ochoa, J.B., et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med 202 (2005), 931–939.
16. [16] Sakaguchi, S., Control of immune responses by naturally arising CD4+ regulatory T cells that express toll-like receptors. J. Exp. Med 197 (2003), 397–401.
17. [17] Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
18. [18] Jacobs, J.F., Nierkens, S., Figdor, C.G., de Vries, I.J., Adema, G.J., Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol 13 (2012), e32–e42.
19. [19] Mougiakakos, D., Choudhury, A., Lladser, A., Kiessling, R., Johansson, C.C., Regulatory T cells in cancer. Adv. Cancer Res 107 (2010), 57–117.
20. [20] Whiteside, T.L., What are regulatory T cells (Treg) regulating in cancer and why?. Semin. Cancer Biol 22 (2012), 327–334.
21. [21] Zou, W., Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol 6 (2006), 295–307.
22. [22] Savage, P.A., Vosseller, K., Kang, C., Larimore, K., Riedel, E., Wojnoonski, K., et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 319 (2008), 215–220.
23. [23] Schietinger, A., Delrow, J.J., Basom, R.S., Blattman, J.N., Greenberg, P.D., Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335 (2012), 723–727.
24. [24] Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
25. [25] Tlsty, T.D., Coussens, L.M., Tumor stroma and regulation of cancer development. Annu. Rev. Pathol 1 (2006), 119–150.
26. [26] Ruffell, B., Au, A., Rugo, H.S., Esserman, L.J., Hwang, E.S., Coussens, L.M., Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 2796–2801.
27. [27] Serafini, P., Borrello, I., Bronte, V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol 16 (2006), 53–65.
28. [28] Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E., Bromberg, J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66 (2006), 1123–1131.
29. [29] Kusmartsev, S., Nefedova, Y., Yoder, D., Gabrilovich, D.I., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol 172 (2004), 989–999.
30. [30] Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23 (2002), 549–555.
31. [31] Chaux, P., Favre, N., Martin, M., Martin, F., Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 72 (1997), 619–624.
32. [32] Friese, M.A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64 (2004), 7596–7603.
33. [33] Gabrilovich, D.I., Corak, J., Ciernik, I.F., Kavanaugh, D., Carbone, D.P., Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res 3 (1997), 483–490.
34. [34] Probst, H.C., Lagnel, J., Kollias, G., van den Broek, M., Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 18 (2003), 713–720.
35. [35] Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol 182 (2009), 4499–4506.
36. [36] Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., Saito, T., Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. U.S.A. 93 (1996), 13119–13124.
37. [37] Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
38. [38] Engelhardt, J.J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21 (2012), 402–417.
39. low regulatory dendritic cells suppress T cell response through arginase I. J. Immunol 182 (2009), 6207–6216.
40. [40] Norian, L.A., Rodriguez, P.C., O'Mara, L.A., Zabaleta, J., Ochoa, A.C., Cella, M., et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res 69 (2009), 3086–3094.
41. [41] Scarlett, U.K., Rutkowski, M.R., Rauwerdink, A.M., Fields, J., Escovar-Fadul, X., Baird, J., et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med 209 (2012), 495–506.
42. [42] Stoitzner, P., Green, L.K., Jung, J.Y., Price, K.M., Atarea, H., Kivell, B., et al. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol. Immunother 57 (2008), 1665–1673.
43. [43] Tesone, A.J., Svoronos, N., Allegrezza, M.J., Conejo-Garcia, J.R., Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. Front Immunol, 4, 2013, 435.
44. [44] Denardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden, S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1 (2011), 54–67.
45. [45] Cavanagh, L.L., Bonasio, R., Mazo, I.B., Halin, C., Cheng, G., van der Velden, A.W., et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat. Immunol 6 (2005), 1029–1037.
46. [46] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95.
47. [47] Dai, F., Liu, L., Che, G., Yu, N., Pu, Q., Zhang, S., et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer, 10, 2010, 220.
48. [48] Kawai, O., Ishii, G., Kubota, K., Murata, Y., Naito, Y., Mizuno, T., et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113 (2008), 1387–1395.
49. [49] Welsh, T.J., Green, R.H., Richardson, D., Waller, D.A., O'Byrne, K.J., Bradding, P., Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol 23 (2005), 8959–8967.
50. [50] Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004), 461–466.
51. [51] Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004), 285–296.
52. [52] Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.Y., Vallabhapurapu, S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15 (2009), 103–113.
53. [53] Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grivennikov, S., Kim, Y., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457 (2009), 102–106.
54. [54] Naugler, W.E., Karin, M., The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med 14 (2008), 109–119.
55. [55] Langowski, J.L., Zhang, X., Wu, L., Mattson, J.D., Chen, T., Smith, K., et al. IL-23 promotes tumour incidence and growth. Nature 442 (2006), 461–465.
56. [56] Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15 (2009), 114–123.
57. [57] von Scheidt, B., Leung, P.S., Yong, M.C., Zhang, Y., Towne, J.E., Smyth, M.J., et al. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. Cancer Res 74 (2014), 2412–2421.
58. [58] Massague, J., TGFbeta in cancer. Cell 134 (2008), 215–230.
59. [59] Pickup, M., Novitskiy, S., Moses, H.L., The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 13 (2013), 788–799.
60. [60] Sartor, M.A., Mahavisno, V., Keshamouni, V.G., Cavalcoli, J., Wright, Z., Karnovsky, A., et al. ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 26 (2010), 456–463.
61. [61] Chaffer, C.L., Weinberg, R.A., A perspective on cancer cell metastasis. Science 331 (2011), 1559–1564.
62. [62] Ferrari, G., Cook, B.D., Terushkin, V., Pintucci, G., Mignatti, P., Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J. Cell. Physiol 219 (2009), 449–458.
63. [63] Mao, Y., Poschke, I., Kiessling, R., Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. J. Intern. Med 276:2 (2014), 154–170.
64. [64] Thomas, D.A., Massague, J., TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8 (2005), 369–380.
65. [65] Schroder, M., Kaufman, R.J., ER stress and the unfolded protein response. Mutat. Res 569 (2005), 29–63.
66. [66] Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H.P., et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287 (2000), 664–666.
67. [67] Hollien, J., Weissman, J.S., Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 313 (2006), 104–107.
68. [68] Yamamoto, K., Sato, T., Matsui, T., Sato, M., Okada, T., Yoshida, H., et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev. Cell 13 (2007), 365–376.
69. [69] Walter, P., Ron, D., The unfolded protein response: from stress pathway to homeostatic regulation. Science 334 (2011), 1081–1086.
70. [70] Lin, J.H., Walter, P., Yen, T.S., Endoplasmic reticulum stress in disease pathogenesis. Annu. Rev. Pathol 3 (2008), 399–425.
71. [71] Marciniak, S.J., Ron, D., Endoplasmic reticulum stress signaling in disease. Physiol. Rev 86 (2006), 1133–1149.
72. [72] Pagliassotti, M.J., Endoplasmic reticulum stress in nonalcoholic fatty liver disease. Annu. Rev. Nutr 32 (2012), 17–33.
73. [73] Ribeiro, C.M., Boucher, R.C., Role of endoplasmic reticulum stress in cystic fibrosis-related airway inflammatory responses. Proc. Am. Thorac. Soc 7 (2010), 387–394.
74. [74] Fernandez, P.M., Tabbara, S.O., Jacobs, L.K., Manning, F.C., Tsangaris, T.N., Schwartz, A.M., et al. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat 59 (2000), 15–26.
75. [75] Uramoto, H., Sugio, K., Oyama, T., Nakata, S., Ono, K., Yoshimastu, T., et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49 (2005), 55–62.
76. [76] Shuda, M., Kondoh, N., Imazeki, N., Tanaka, K., Okada, T., Mori, K., et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J. Hepatol 38 (2003), 605–614.
77. [77] Xing, X., Lai, M., Wang, Y., Xu, E., Huang, Q., Overexpression of glucose-regulated protein 78 in colon cancer. Clin. Chim. Acta 364 (2006), 308–315.
78. [78] Daneshmand, S., Quek, M.L., Lin, E., Lee, C., Cote, R.J., Hawes, D., et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum. Pathol 38 (2007), 1547–1552.
79. [79] Pyrko, P., Schonthal, A.H., Hofman, F.M., Chen, T.C., Lee, A.S., The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67 (2007), 9809–9816.
80. [80] Arap, M.A., Lahdenranta, J., Mintz, P.J., Hajitou, A., Sarkis, A.S., Arap, W., et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6 (2004), 275–284.
81. [81] Davidson, D.J., Haskell, C., Majest, S., Kherzai, A., Egan, D.A., Walter, K.A., et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 65 (2005), 4663–4672.
82. [82] Li, J., Lee, A.S., Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med 6 (2006), 45–54.
83. [83] Misra, U.K., Deedwania, R., Pizzo, S.V., Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J. Biol. Chem 281 (2006), 13694–13707.
84. [84] Chang, J.T., Palanivel, V.R., Kinjyo, I., Schambach, F., Intlekofer, A.M., Banerjee, A., et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315 (2007), 1687–1691.
85. [85] Fu, Y., Li, J., Lee, A.S., GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res 67 (2007), 3734–3740.
86. [86] Ranganathan, A.C., Zhang, L., Adam, A.P., Aguirre-Ghiso, J.A., Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 66 (2006), 1702–1711.
87. [87] Reddy, R.K., Mao, C., Baumeister, P., Austin, R.C., Kaufman, R.J., Lee, A.S., Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J. Biol. Chem 278 (2003), 20915–20924.
88. [88] Lee, A.S., Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 14 (2014), 263–276.
89. [89] Fu, Y., Wey, S., Wang, M., Ye, R., Liao, C.P., Roy-Burman, P., et al. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 19444–19449.
90. [90] Lin, Y.G., Shen, J., Yoo, E., Liu, R., Yen, H.Y., Mehta, A., et al. Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis. Oncogene, 2015, 10.1038/onc.2015.4.
91. [91] Dong, D., Ni, M., Li, J., Xiong, S., Ye, W., Virrey, J.J., et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 68 (2008), 498–505.
92. [92] Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.H., Yoshida, H., et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res 64 (2004), 5943–5947.
93. [93] Romero-Ramirez, L., Cao, H., Regalado, M.P., Kambham, N., Siemann, D., Kim, J.J., et al. X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. Transl. Oncol 2 (2009), 31–38.
94. [94] Drogat, B., Auguste, P., Nguyen, D.T., Bouchecareilh, M., Pineau, R., Nalbantoglu, J., et al. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res 67 (2007), 6700–6707.
95. [95] Chen, X., Iliopoulos, D., Zhang, Q., Tang, Q., Greenblatt, M.B., Hatziapostolou, M., et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 508 (2014), 103–107.
96. [96] Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
97. [97] Yu, M., Bardia, A., Wittner, B.S., Stott, S.L., Smas, M.E., Ting, D.T., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339 (2013), 580–584.
98. [98] Idowu, M.O., Kmieciak, M., Dumur, C., Burton, R.S., Grimes, M.M., Powers, C.N., et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol 43 (2012), 364–373.
99. [99] Bi, M., Naczki, C., Koritzinsky, M., Fels, D., Blais, J., Hu, N., et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 24 (2005), 3470–3481.
100. [100] Lin, J.H., Li, H., Yasumura, D., Cohen, H.R., Zhang, C., Panning, B., et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 318 (2007), 944–949.
101. [101] Tam, A.B., Koong, A.C., Niwa, M., Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD. Cell Rep 9 (2014), 850–858.
102. [102] Han, D., Lerner, A.G., Vande Walle, L., Upton, J.P., Xu, W., Hagen, A., et al. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 138 (2009), 562–575.
103. [103] Chen, Y., Brandizzi, F., IRE1: ER stress sensor and cell fate executor. Trends Cell Biol 23 (2013), 547–555.
104. [104] Chitnis, N.S., Pytel, D., Bobrovnikova-Marjon, E., Pant, D., Zheng, H., Maas, N.L., et al. miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner. Mol. Cell 48 (2012), 353–364.
105. [105] Wheeler, M.C., Rizzi, M., Sasik, R., Almanza, G., Hardiman, G., Zanetti, M., KDEL-retained antigen in B lymphocytes induces a proinflammatory response: a possible role for endoplasmic reticulum stress in adaptive T cell immunity. J. Immunol 181 (2008), 256–264.
106. [106] Mahadevan, N.R., Fernandez, A., Rodvold, J., Almanza, G., Zanetti, M., Prostate cells undergoing ER stress in vitro and in vivo activate transcription of pro-inflammatory cytokines. J. Inflamm Res 3 (2010), 99–103.
107. [107] Goodall, J.C., Wu, C., Zhang, Y., McNeill, L., Ellis, L., Saudek, V., et al. Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 17698–17703.
108. [108] Chen, L., Jarujaron, S., Wu, X., Sun, L., Zha, W., Liang, G., et al. HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages. Biochem. Pharmacol 78 (2009), 70–77.
109. [109] Tam, A.B., Mercado, E.L., Hoffmann, A., Niwa, M., ER stress activates NF-kappaB by integrating functions of basal IKK activity, IRE1 and PERK. PLoS ONE, 7, 2012, e45078.
110. [110] Deng, J., Lu, P.D., Zhang, Y., Scheuner, D., Kaufman, R.J., Sonenberg, N., et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol. Cell. Biol 24 (2004), 10161–10168.
111. [111] Jiang, H.Y., Wek, S.A., McGrath, B.C., Scheuner, D., Kaufman, R.J., Cavener, D.R., et al. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol. Cell. Biol 23 (2003), 5651–5663.
112. [112] Hu, P., Han, Z., Couvillon, A.D., Kaufman, R.J., Exton, J.H., Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol. Cell. Biol 26 (2006), 3071–3084.
113. [113] Yamazaki, H., Hiramatsu, N., Hayakawa, K., Tagawa, Y., Okamura, M., Ogata, R., et al. Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. J. Immunol 183 (2009), 1480–1487.
114. [114] Martinon, F., Chen, X., Lee, A.H., Glimcher, L.H., TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat. Immunol 11 (2010), 411–418.
115. [115] DeLay, M.L., Turner, M.J., Klenk, E.I., Smith, J.A., Sowders, D.P., Colbert, R.A., HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 60 (2009), 2633–2643.
116. [116] Eletto, D., Dersh, D., Argon, Y., GRP94 in ER quality control and stress responses. Semin. Cell Dev. Biol 21 (2010), 479–485.
117. [117] Yang, Y., Li, Z., Roles of heat shock protein gp96 in the ER quality control: redundant or unique function?. Mol. Cells 20 (2005), 173–182.
118. [118] Yang, Y., Liu, B., Dai, J., Srivastava, P.K., Zammit, D.J., Lefrancois, L., et al. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 26 (2007), 215–226.
119. [119] Liu, B., Yang, Y., Qiu, Z., Staron, M., Hong, F., Li, Y., et al. Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone. Nat. Commun, 1, 2010, 79.
120. [120] Morales, C., Rachidi, S., Hong, F., Sun, S., Ouyang, X., Wallace, C., et al. Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Res 74 (2014), 446–459.
121. [121] Zhang, Y., Wu, B.X., Metelli, A., Thaxton, J.E., Hong, F., Rachidi, S., et al. GP96 is a GARP chaperone and controls regulatory T cell functions. J. Clin. Invest 125 (2015), 859–869.
122. [122] de Almeida, S.F., Fleming, J.V., Azevedo, J.E., Carmo-Fonseca, M., de Sousa, M., Stimulation of an unfolded protein response impairs MHC class I expression. J. Immunol 178 (2007), 3612–3619.
123. [123] Granados, D.P., Tanguay, P.L., Hardy, M.P., Caron, E., de Verteuil, D., Meloche, S., et al. ER stress affects processing of MHC class I-associated peptides. BMC Immunol, 10, 2009, 10.
124. [124] Howarth, M., Williams, A., Tolstrup, A.B., Elliott, T., Tapasin enhances MHC class I peptide presentation according to peptide half-life. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 11737–11742.
125. [125] Pellicciotta, I., Cortez-Gonzalez, X., Sasik, R., Reiter, Y., Hardiman, G., Langlade-Demoyen, P., et al. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. Cancer Res 68 (2008), 8085–8093.
126. [126] Bartoszewski, R., Brewer, J.W., Rab, A., Crossman, D.K., Bartoszewska, S., Kapoor, N., et al. The unfolded protein response (UPR)-activated transcription factor X-box-binding protein 1 (XBP1) induces microRNA-346 expression that targets the human antigen peptide transporter 1 (TAP1) mRNA and governs immune regulatory genes. J. Biol. Chem 286 (2011), 41862–41870.
127. [127] Osorio, F., Tavernier, S.J., Hoffmann, E., Saeys, Y., Martens, L., Vetters, J., et al. The unfolded-protein-response sensor IRE-1alpha regulates the function of CD8alpha(+) dendritic cells. Nat. Immunol 15 (2014), 248–257.
128. [128] Mahadevan, N.R., Anufreichik, V., Rodvold, J.J., Chiu, K.T., Sepulveda, H., Zanetti, M., Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8(+) T cell priming. PLoS ONE, 7, 2012, e51845.
129. [129] Mahadevan, N.R., Rodvold, J., Sepulveda, H., Rossi, S., Drew, A.F., Zanetti, M., Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 6561–6566.
130. [130] Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol 5 (2005), 641–654.
131. [131] Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol 12 (2012), 253–268.
132. [132] Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med 192 (2000), 1027–1034.
133. [133] Cullen, S.J., Fatemie, S., Ladiges, W., Breast tumor cells primed by endoplasmic reticulum stress remodel macrophage phenotype. Am. J. Cancer Res 3 (2013), 196–210.
134. [134] Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol 8 (2008), 958–969.
135. [135] Mantovani, A., Sica, A., Allavena, P., Garlanda, C., Locati, M., Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol 70 (2009), 325–330.
136. [136] Thevenot, P.T., Sierra, R.A., Raber, P.L., Al-Khami, A.A., Trillo-Tinoco, J., Zarreii, P., et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41 (2014), 389–401.
137. [137] Cubillos-Ruiz, J.R., Silberman, P.C., Rutkowski, M.R., Chopra, S., Perales-Puchalt, A., Song, M., et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161 (2015), 1527–1538.
138. [138] Condamine, T., Kumar, V., Ramachandran, I.R., Youn, J.I., Celis, E., Finnberg, N., et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J. Clin. Invest 124 (2014), 2626–2639.
139. [139] Mahadevan, N.R., Zanetti, M., Tumor stress inside out: cell-extrinsic effects of the unfolded protein response in tumor cells modulate the immunological landscape of the tumor microenvironment. J. Immunol 187 (2011), 4403–4409.
140. [140] Beverly, B., Kang, S.M., Lenardo, M.J., Schwartz, R.H., Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol 4 (1992), 661–671.
141. [141] Ishida, Y., Agata, Y., Shibahara, K., Honjo, T., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11 (1992), 3887–3895.
142. [142] Grosso, J.F., Kelleher, C.C., Harris, T.J., Maris, C.H., Hipkiss, E.L., De Marzo, A., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest 117 (2007), 3383–3392.
143. [143] Becker, J.C., Vetter, C.S., Schrama, D., Brocker, E.-B., Straten, P.T., Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. Eur. J. Immunol 30 (2000), 3699–3706.
144. [144] Filaci, G., Fenoglio, D., Fravega, M., Ansaldo, G., Borgonovo, G., Traverso, P., et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J. Immunol 179 (2007), 4323–4334.
145. [145] Kruger, K., Buning, C., Schriever, F., Activated T lymphocytes bind in situ to stromal tissue of colon carcinoma but lack adhesion to tumor cells. Eur. J. Immunol 31 (2001), 138–145.
146. [146] Mahic, M., Henjum, K., Yaqub, S., Bjornbeth, B.A., Torgersen, K.M., Tasken, K., et al. Generation of highly suppressive adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation. Eur. J. Immunol 38 (2008), 640–646.
147. [147] Steinman, R.M., Hawiger, D., Nussenzweig, M.C., Tolerogenic dendritic cells. Annu. Rev. Immunol 21 (2003), 685–711.
148. [148] Steinman, R.M., Nussenzweig, M.C., Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 351–358.
149. [149] Jamora, C., Dennert, G., Lee, A.S., Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc. Natl. Acad. Sci. U.S.A. 93 (1996), 7690–7694.
150. [150] Wang, M., Wang, P., Liu, Y.Q., Peng, J.L., Zhao, X.P., Wu, S., et al. The immunosuppressive and protective ability of glucose-regulated protein 78 for improvement of alloimmunity in beta cell transplantation. Clin. Exp. Immunol 150 (2007), 546–552.
151. [151] Ueda, J.Y., Chijiwa, S., Takagi, M., Shin-Ya, K., A novel versipelostatin analogue, versipelostatin F isolated from streptomyces versipellis 4083-SVS6. J. Antibiot. (Tokyo) 61 (2008), 752–755.
152. [152] Park, H.R., Chijiwa, S., Furihata, K., Hayakawa, Y., Shin-Ya, K., Relative and absolute configuration of versipelostatin, a down-regulator of molecular chaperone GRP78 expression. Org. Lett 9 (2007), 1457–1460.
153. [153] Rasche, L., Duell, J., Morgner, C., Chatterjee, M., Hensel, F., Rosenwald, A., et al. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78. PLoS ONE, 8, 2013, e63414.
154. [154] Liu, R., Li, X., Gao, W., Zhou, Y., Wey, S., Mitra, S.K., et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin. Cancer Res 19 (2013), 6802–6811.
155. [155] Ermakova, S.P., Kang, B.S., Choi, B.Y., Choi, H.S., Schuster, T.F., Ma, W.Y., et al. Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 66 (2006), 9260–9269.
156. [156] Papandreou, I., Denko, N.C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 117 (2011), 1311–1314.
157. [157] Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.T., Cirstea, D., Santo, L., et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 119 (2012), 5772–5781.
158. [158] Cross, B.C., Bond, P.J., Sadowski, P.G., Jha, B.K., Zak, J., Goodman, J.M., et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), E869–E878.
159. [159] Ri, M., Tashiro, E., Oikawa, D., Shinjo, S., Tokuda, M., Yokouchi, Y., et al. Identification of toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J, 2, 2012, e79.
160. [160] Axten, J.M., Medina, J.R., Feng, Y., Shu, A., Romeril, S.P., Grant, S.W., et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J. Med. Chem 55 (2012), 7193–7207.
161. [161] Sidrauski, C., Acosta-Alvear, D., Khoutorsky, A., Vedantham, P., Hearn, B.R., Li, H., et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife, 2, 2013, e00498.
162. [162] Denmeade, S.R., Mhaka, A.M., Rosen, D.M., Brennen, W.N., Dalrymple, S., Dach, I., et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci. Transl. Med, 4, 2012, 140ra186.
163. [163] Kardosh, A., Golden, E.B., Pyrko, P., Uddin, J., Hofman, F.M., Chen, T.C., et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 68 (2008), 843–851.
164. [164] Lee, A.H., Iwakoshi, N.N., Anderson, K.C., Glimcher, L.H., Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 9946–9951.
165. [165] Yoshida, T., Shiraishi, T., Nakata, S., Horinaka, M., Wakada, M., Mizutani, Y., et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65 (2005), 5662–5667.
166. [166] Yao, X., Zhu, F., Zhao, Z., Liu, C., Luo, L., Yin, Z., Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. J. Cell. Biochem 112 (2011), 2837–2849.
167. [167] Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med 11 (2005), 1314–1321.
168. [168] Jiang, D., Niwa, M., Koong, A.C., Targeting the IRE1alpha-XBP1 branch of the unfolded protein response in human diseases. Semin. Cancer Biol 33 (2015), 48–56.
169. [169] Cojocari, D., Vellanki, R.N., Sit, B., Uehling, D., Koritzinsky, M., Wouters, B.G., New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1alpha signaling is essential for promoting adaptation and survival to hypoxia. Radiother. Oncol 108 (2013), 541–547.
170. [170] Boyce, M., Bryant, K.F., Jousse, C., Long, K., Harding, H.P., Scheuner, D., et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307 (2005), 935–939.
171. [171] Tsaytler, P., Harding, H.P., Ron, D., Bertolotti, A., Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 332 (2011), 91–94.
172. [172] Hamamura, K., Minami, K., Tanjung, N., Wan, Q., Koizumi, M., Matsuura, N., et al. Attenuation of malignant phenotypes of breast cancer cells through eIF2alpha-mediated downregulation of Rac1 signaling. Int. J. Oncol 44 (2014), 1980–1988.
173. [173] Fels, D.R., Ye, J., Segan, A.T., Kridel, S.J., Spiotto, M., Olson, M., et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 68 (2008), 9323–9330.
174. [174] Nawrocki, S.T., Carew, J.S., Pino, M.S., Highshaw, R.A., Dunner, K. Jr., Huang, P., et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65 (2005), 11658–11666.
175. [175] Angell, H., Galon, J., From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol 25 (2013), 261–267.
176. [176] Galon, J., Angell, H.K., Bedognetti, D., Marincola, F.M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26.
177. [177] Fenoglio, D., Ferrera, F., Fravega, M., et al. Advancements on phenotypic and functional characterization of non-antigen-specific CD8+CD28- regulatory T cells. Hum. Immunol 69 (2008), 745–750.
178. [178] Parodi, A., Battaglia, F., Kalli, F., et al. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunol. Immunother 62 (2013), 851–862.
179. [179] Wei, C.H., Trenney, R., Sanchez-Alavez, M., et al. Tissue-resident memory CD8+ T cells can be deleted by soluble, but not cross-presented antigen. J. Immunol 175 (2005), 6615–6623.